Please login to the form below

Not currently logged in
Email:
Password:

Chiltern hires Roche’s Andrew Monaghan to head pharmacovigilance

He was global head of safety operations at pharma company

Roche's Andrew Monaghan has swapped pharma for clinical research by moving to Chiltern.

Monaghan, who was global head of safety operations at Roche, take on the role of director of global pharmacovigilance at the clinical research organisation Chiltern.

In this new role, he will lead Chiltern's pharmacovigilance team and expand the organisation's global pharmacovigilance offering.

“His strong leadership skills and extensive clinical experience will ensure our clients continue to receive customized and efficient safety solutions to meet their specific product and regulatory requirements, whether with investigational or postmarketed products,” said Dr Sharon Moore, executive VP, global medical and regulatory affairs.

Monaghan has served at Roche since 1997, when he joined as global head of PDO clinical management group.

Prior to this role he was director of regulatory affairs at Pfizer Global Research & Development.

25th July 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics